Observational studyJournal of cardiothoracic surgery2026
Prognostic value of X-box binding protein 1 and phospholipase A2 in myocardial injury after ST-segment elevation myocardial infarction: a prospective observational study.
Observational study in Journal of cardiothoracic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study explored the role of X-box binding protein 1 (XBP1), phospholipase A2 (PLA2), and B-type natriuretic peptide (BNP) as biomarkers for diagnosing and predicting myocardial injury in patients with ST-segment elevation acute myocardial infarction (STEMI).
methodsThis prospective cohort study enrolled 283 adult patients with Acute Coronary Syndrome (ACS) admitted to Tianjin Third Central Hospital between October 2021 and October 2022. Patient selection followed strict criteria: inclusion required ACS diagnosis or high ACS risk with informed consent; exclusion criteria were history of myocardial infarction, ejection fraction < 30%, or comorbidities (e.g., cardiomyopathy, renal disease). Patients were divided into STEMI and non-STEMI/unstable angina groups based on electrocardiogram findings. Serum levels of XBP1, PLA2, and other related indicators were measured using enzyme-linked immunosorbent assay (ELISA) kits. The relationships between these biomarkers and myocardial injury were analyzed.
resultsXBP1 and PLA2 levels were significantly elevated in patients with myocardial ischemia-reperfusion injury (MIRI), myocardial injury, and those undergoing intervention. Recombinant human BNP (rhBNP) treatment was associated with lower XBP1 and PLA2 levels 24 h post-surgery. Logistic regression analysis identified smoking history, neutrophil percentage, sICAM-1, and PLA2 as independent risk factors for myocardial injury. XBP1, PLA2, and BNP levels were independently related to myocardial injury and showed significant positive correlations with each other. ROC curve analysis indicated that XBP1 and PLA2 levels had significant diagnostic efficacy for postoperative myocardial injury, with the combined diagnostic approach yielding the best performance.
conclusionPre-treatment serum PLA2 and XBP1 levels, alone or in combination, may serve as significant predictors of myocardial injury in ACS patients undergoing PCI. rhBNP may protect the myocardium and improve cardiac function by reducing XBP1 and PLA2 levels. These findings suggest that pre-treatment serum PLA2 and XBP1 levels could be used as practical biomarkers for risk stratification in ACS patients undergoing PCI, aiding clinicians in decision-making regarding rhBNP therapy. Further studies are needed to validate these results and integrate them into clinical guidelines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.